Evaluation of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch.
In a multicentre, blinded, placebo-controlled trial, 50 dogs were treated for 28 days with either phenylpropanolamine or a placebo control. Each was given at a dose of one drop per 2 kg orally three times daily, equivalent to 1 mg/kg three times daily of phenylpropanolamine. Dogs that presented with clinical signs consistent with urinary sphincter mechanism incontinence were included in the study. They were examined on three occasions by the investigating veterinary surgeon. The frequency and volume of unconscious urination were scored by veterinary surgeons according to a pre-established scoring system. Phenylpropanolamine proved to be more effective than the placebo in regard to several parameters. At day 28, 85.7 per cent of phenylpropanolamine-treated cases had no episodes of unconscious urination compared with 33.3 per cent of placebo-treated cases. This was statistically significant. Few, mild side effects were seen in either group.
Scott
L
L
Vétoquinol (UK) Ltd, Wedgewood Road, Bicester, Oxon OX26 7UL.
Leddy
M
M
Bernay
F
F
Davot
J L
JL
D000284:Administration, Oral; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014521:Urethra / Q000503:physiopathology; D014550:Urinary Incontinence, Stress / Q000188:drug therapy / Q000662:veterinary*; D014563:Urodynamics
D000316:Adrenergic alpha-Agonists; D010665:Phenylpropanolamine